Caricamento...
Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit?
BACKGROUND: Neoadjuvant therapies (neoTx) have revolutionized the treatment of borderline resectable (BR) and locally advanced (LA) pancreatic cancer (PCa) by significantly increasing the rate of R0 resections, which remains the only curative strategy for these patients. However, there is still room...
Salvato in:
| Pubblicato in: | Langenbecks Arch Surg |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Berlin Heidelberg
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7541356/ https://ncbi.nlm.nih.gov/pubmed/32776259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00423-020-01946-4 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|